¹ÙÀÌ¿ÀÀǾàǰ »ê¾÷ ÇöȲ(2024³âÆÇ)
The State of the Biopharmaceutical Industry 2024 Edition
»óǰÄÚµå
:
1405163
¸®¼Ä¡»ç
:
GlobalData
¹ßÇàÀÏ
:
2023³â 12¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 110 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
COVID-19¿ÍÀÇ ½Î¿òÀº ¸Õ °ú°ÅÀÇ ÀÏÀÌ ¾Æ´ÏÁö¸¸, °Å½Ã°æÁ¦ ¹× ÁöÁ¤ÇÐÀû ¿äÀÎÀ¸·Î ÀÎÇØ ÀÌ¹Ì ±×´ÃÀÌ µå¸®¿öÁ® ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ÁøÇà ÁßÀÎ ¾à°¡ ¹× »óȯ Á¦¾à, ±ÔÁ¦ ´ç±¹ÀÇ ¾Ð·Â, »ý¸í°øÇÐ ±â¾÷ÀÇ ÀÚ±Ý Á¶´ÞÀÇ ºÒ¾ÈÁ¤¼º µîÀº ÇâÈÄ ¸î ³â µ¿¾È Á¦¾à »ê¾÷À» ½ÃÇè¿¡ ºü¶ß¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- COVID-19 ÀÌÈÄ È¸º¹¿¡´Â °Å½Ã°æÁ¦Àû, ÁöÁ¤ÇÐÀûÀ¸·Î ´Ù¾çÇÑ µµÀüÀÌ ÀÖ½À´Ï´Ù.
- À¯ÀüüÇÐ, IO ÀǾàǰ °³¹ß, °³ÀÎÈ/Á¤¹ÐÀÇ·á, CGT´Â 2024³â ¹ÙÀÌ¿ÀÀǾàǰ »ê¾÷¿¡¼ ´õ¿í ¿µÇâ·Â ÀÖ´Â Æ®·»µå·Î ¿ìÀ§¸¦ Á¡ÇÒ °ÍÀÔ´Ï´Ù.
- °¡Àå ¿µÇâ·Â ÀÖ´Â Æ®·»µå Áß ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á´Â 2024³â¿¡ Áß¿äÇÑ ÃÊÁ¡ÀÌ µÉ °ÍÀÔ´Ï´Ù.
- ÁöÁ¤ÇÐÀû ºÐÀï, ÀÎÇ÷¹À̼Ç, ¾à°¡ ¾Ð¹ÚÀº Á¦¾à ºÎ¹®ÀÇ ¼ºÀåÀ» ¾ïÁ¦ÇÏ´Â °¡Àå Å« ¿äÀÎÀÔ´Ï´Ù.
- ¼öÁ÷ ÅëÇÕ, »ý¹°ÇÐÀû Á¦Á¦ ƯÇã ¸¸·á, ESG ¿äÀÎÀÌ Á¦¾à»ê¾÷¿¡ °¡Àå Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ºòµ¥ÀÌÅÍ¿Í AI´Â 2024³â¿¡µµ ÀÇ·á ºÎ¹®ÀÇ º¯ÇõÀû ÈûÀ¸·Î °è¼Ó ¿ìÀ§¸¦ Á¡ÇÒ °ÍÀÔ´Ï´Ù.
- Á¦¾à °¡Ä¡»ç½½ÀÇ Àüü ±¸¼º¿ä¼Ò¿¡¼ ÀǾàǰ °³¹ß ¹× ÃÖÁ¾»ç¿ëÀÚ °æÇèÀº Çõ½Å äÅÿ¡¼ µÚÃÄÁ® ÀÖ½À´Ï´Ù.
- ¹ÙÀÌ¿ÀÀǾàǰ ¾÷°è´Â 2023³â ´ëºñ ÇâÈÄ 1³â°£ÀÇ »ê¾÷ ¼ºÀå¿¡ ´ëÇØ ³«°üÀûÀÌÁö¸¸, ³«°üÀûÀÎ ¼öÁØÀº ¿©ÀüÈ÷ 2022³â ¼öÁغ¸´Ù ³·½À´Ï´Ù.
- Á¶»ç ÀÀ´äÀÚÀÇ 44%´Â 2024³â »ý¸í°øÇÐ ÀÚ±Ý Á¶´Þ ȸº¹¿¡ ´ëÇØ ³«°üÀûÀ̰ųª ¸Å¿ì ³«°üÀûÀ̶ó°í ´äÇß½À´Ï´Ù.
- 2023³â ÀÓ»ó½ÃÇèÀÌ ½ÃÀÛµÉ ºÐ¾ß´Â ¾Ï, ÁßÃ߽Űæ°è, °¨¿°ÁúȯÀÌ ÁÖ¸¦ ÀÌ·ì´Ï´Ù.
- 2024³â±îÁö ¾ÏÀÌ ¿©ÀüÈ÷ °¡Àå Å« Ä¡·á ¿µ¿ªÀÌÁö¸¸, ´ë»ç¼º ÁúȯÀÌ °¡Àå ³ôÀº ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- IRA´Â ¸ðµç ÀǾàǰ¿¡ ´ëÇÑ Á¤ºÎÀÇ °¡°Ý Çù»óÀÇ ¹®À» ¿©´Â °ÍÀ¸·Î °£Áֵ˴ϴÙ.
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- 2024³â¿¡ ¾ÈÁ¤¼ºÀ» ³ôÀÏ °ÍÀ¸·Î ¿¹»óµÇÁö¸¸, ¾ÆÁ÷ °¥ ±æÀÌ ¸Ù´Ï´Ù.
- CGT´Â 2024³â¿¡µµ ÀǾàǰ »ê¾÷¿¡ °¡Àå Å« ¿µÇâÀ» ¹ÌÄ¥ Æ®·»µåÀÔ´Ï´Ù.
- ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐÀû ºÐÀï, ¾à°¡ ¹× »óȯ °ü·Ã ¿ì·Á´Â »ê¾÷ ¼ºÀåÀ» ¾ïÁ¦ÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ¼öÁ÷ ÅëÇÕ, »ý¹°ÇÐÀû Á¦Á¦ ƯÇã ¸¸·á, ESG ¿äÀÎÀÌ »ê¾÷¿¡ °¡Àå À¯¸®ÇÑ ¿µÇâÀ» ¹ÌĨ´Ï´Ù.
- AI°¡ Á¦¾à »ê¾÷¿¡ ÆÄ±«Àû º¯È¸¦ °¡Á®¿Ã Àü¸ÁÀÔ´Ï´Ù.
- Á¦¾à ºÎ¹® ¼ºÀå Àü¸Á¿¡ ´ëÇÑ ³«°ü·ÐÀº 2023³â ÃÖÀú ¼öÁØ¿¡¼ ȸº¹µÇ¾ú½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ¿¬±¸ µðÀÚÀÎ
Á¦3Àå »õ·Î¿î »ê¾÷ µ¿Çâ
Á¦4Àå »õ·Î¿î ±ÔÁ¦¿Í °Å½Ã°æÁ¦ µ¿Çâ
Á¦5Àå ½Å±â¼ú
Á¦6Àå »ê¾÷ÀÇ ¼ºÀå Àü¸Á
Á¦7Àå ÁÖÀÇ
Á¦8Àå ÁÖ¿ä Á¶»ç °á°ú ¿ä¾à
Á¦9Àå ºÎ·Ï
Á¦10Àå ÀúÀÚ, ±â°íÀÚ
Á¦11Àå Thematic ResearchÀÇ Á¶»ç ¹æ¹ý
Á¦12Àå ¿¬¶ôó
ksm
¿µ¹® ¸ñÂ÷
Abstract
While the fight against COVID-19 is not in the distant past, it has been already overshadowed by a range of macroeconomic and geopolitical factors. At the same time, ongoing drug pricing and reimbursement constraints, regulatory pressures, and biotech funding instability will continue to test pharmaceutical industry in the coming years. In this "Thematic Intelligence: The State of the Biopharmaceutical Industry 2024 Edition" report, GlobalData examines the business environment and trends that are going to shape the biopharmaceutical industry in 2024. The report highlights the most impactful emerging technologies, industry trends, regulatory trends, and microeconomic factors that are going to impact and dominate the industry throughout 2024.
- Post-COVID-19 recovery is met by a range of macroeconomic and geopolitical challenges.
- Genomics, IO drug development, personalized/precision medicine and CGTs will dominate as the most impactful trends in the biopharmaceutical industry in 2024.
- Among the most impactful trends, cell and gene therapies will be the key focus in 2024.
- Geopolitical conflicts, inflation, and drug pricing pressures will be the top hindrances for pharmaceutical sector growth.
- Vertical integration, patent expiry of biologics, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry.
- Big data and AI will continue to dominate as transformational forces in the healthcare sector in 2024.
- Across pharma value chain components, drug development and end users experience are lagging behind with innovation adoption.
- The biopharmaceutical industry is more optimistic about industry growth in the next 12 months as compared to 2023, but level of optimism is still below 2022 levels.
- A total of 44% of survey respondents expressed an optimistic or very optimistic sentiment on the biotech funding recovery in 2024.
- Oncology, CNS, and infectious diseases will be the dominant areas for clinical trials initiated in 2023.
- Oncology remains the single largest therapy area going into 2024, but metabolic disorders display the highest growth.
- The IRA is believed to open the door to government price negotiation across all pharmaceuticals.
Key Highlights
- There is hope for more stability in 2024, but the road is still rocky.
- CGT is the trend that will continue to have the greatest impact on the pharmaceutical industry in 2024.
- Inflation, geopolitical conflicts, and drug pricing and reimbursement-related concerns will be the leading impediment to industry growth.
- Vertical integration, patent expiry of biologics, and ESG factors will have the most positive impacts on industry.
- AI is set to bring disruptive change in pharmaceutical industry
- Optimism about the pharmaceutical sector's growth prospects recovered from the lows seen in 2023.
Scope
- Benchmark the impact of major themes on the biopharmaceutical industry in 2024, including: emerging technologies, regulatory trends, macroeconomic trends, industry trends.
- Identify themes that will have the greatest positive or negative impact in 2024.
- Capture opinions on these themes from industry respondents.
- Predict the industry's growth prospects in 2024.
Reasons to Buy
- Stay up to date with the major emerging technologies, regulatory, macroeconomic, and industry trends that will impact the pharmaceutical industry in 2024.
- Explore how the biopharmaceutical landscape has changed.
- Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2024.
- Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry.
- Identify emerging industry trends and innovations to gain a competitive advantage.
Table of Contents
Table of Contents
1. Executive Summary
2. Study Design
3. Emerging Industry Trends
4. Emerging Regulatory and Macroeconomic Trends
5. Emerging Technologies
6. Industry's Growth Prospects
7. Watch Outs
8. Summary of Key Findings
9. Appendix
10. Authors and Contributors
11. Our Thematic Research Methodology
12. Contact Us
°ü·ÃÀÚ·á